BioSpace News Archive

Deals

GSK Is Now Favorite to Acquire Pfizer’s Consumer Health Business

Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business.

March 22, 2018
·
2 min read
·
Alex Keown
4 Things to Do When You Transition from Manager to Leader

For some, making the seismic shift from department or team manager to true company or industry leader at a large-scale level is not a natural transition and requires some retooling in the way they approach and solve problems, communicate, strategize, and view the business and industry as a whole.

March 22, 2018
·
3 min read
Drug Development

Poor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug

After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug.

March 22, 2018
·
2 min read
·
Mark Terry
Drug Development

Array BioPharma Touts Phase III Results for Melanoma Therapy

Array BioPharma Inc. released detailed results for its late-stage combination treatment for metastatic melanoma.

March 22, 2018
·
2 min read
·
Alex Keown
Biotech Beach

Arena Pharma Raising $352 Million Following Positive Phase II Data

Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.

March 22, 2018
·
2 min read
·
Mark Terry
Genetown

Rheos Medicines Launches with $60 Million

Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.

March 22, 2018
·
3 min read
·
Mark Terry
Business

Regeneron and Alnylam Team up to Tackle NASH Liver Disease

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.

March 22, 2018
·
2 min read
·
Mark Terry
U.S. House Passes Right-to-Try Legislation on Second Attempt

The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the approval of the U.S. FDA.

March 22, 2018
·
2 min read
·
Alex Keown
Business

Invitae expands network of patients in rare and ultra-rare diseases

-- No Stomach for Cancer among five advocacy groups establishing registry networks to connect patients, clinicians and researchers --

March 22, 2018
·
6 min read
FDA

Teva Canada Announces the Launch of C ACT Methylphenidate ER Tablets

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for CACT Methylphenidate ER® tablets, the generic version of CConcerta® (methylphenidate hydrochloride).

March 22, 2018
·
4 min read